Autism, Yeast Candida Infections and Associated Illness’s

Safety profile of Terbinafine [Lamisil]
The frequency of reported apparent hepatic dysfunctions has varied. An
analysis of 7 key placebo-controlled trials (262 placebo vs 1624 terbinafine
patients) suggested increases of 1.4% vs 3.4% in liver function test
indicators (APase, AST, ALT, g-GT, bilirubin >2x above upper normal). In a
European postmarketing study in 25 884 patients, asymptomatic liver enzyme
increases were reported in 0.17% of patients treated. The reporting
frequency for symptomatic liver disorder possibly related to terbinafine was
1:13 000. The relative risk of acute liver injury in this group was
considered to be 4.2 times the background incidence. In the less controlled
circumstances of spontaneous worldwide reporting, the development of
clinically significant signs and symptoms of hepatobiliary dysfunction for
which no other cause was apparent, and in which terbinafine was considered
the possible causative agent was calculated to be approximately 1:37 000
treated patients. The reporting frequency overall for hepatobiliary events
including elevations in liver enzymes was 1:15 000. Very rare cases of liver
failure, some fatal, have been associated with terbinafine treatment and the
incidence rate is about 1:1 000 000 exposed patients

Fluconazole Safety
Fluconazole is generally well tolerated over a wide dose range.
Clinical experience is extensive, with over 16 million patient-days of
treatment with fluconazole since its introduction in the UK, and 300 million
patient-days world-wide. The incidence of side effects is low, and symptoms
are generally mild and do not require discontinuation from therapy.7 The
most common side effects are associated with the gastrointestinal tract
(nausea, abdominal discomfort, vomiting, diarrhoea). Others include headache
and rashes, but these are rarely encountered (incidence of <2%).
Tolerability is high even in special patient groups including children and
severely ill patients with AIDS or cancer.
Although not licensed, high doses of fluconazole (up to 800 mg/day) are well
tolerated in the treatment of immunocompromised patients with severe
systemic mycoses.86,87 Doses of up to 1600 mg fluconazole have been shown to
be well tolerated in studies of AIDS patients with histoplasmosis88 and
cryptococcal meningitis.
In rare cases, particularly in patients with serious underlying diseases
such as AIDS and cancer, abnormalities of hepatic, renal, haematological and
other biochemical function tests have been observed, but the clinical
significance and relationship of these to treatment is uncertain.7 Very
rarely, post-mortem examinations of patients who died with severe underlying
disease and had received multiple-dose fluconazole therapy have revealed
hepatic necrosis: an assessment of the risk–benefit ratio of continued
fluconazole administration for patients in whom a significant rise in liver
enzymes occurs is, therefore, recommended.

Safety profile with children

The safety profile of fluconazole was assessed for 562 children (ages, 0 to 17 years) comprising 323 males and 239 females. The data are derived from 12 clinical studies of fluconazole as prophylaxis or treatment for a variety of fungal infections in predominantly immunocompromised patients. Most children received multiple doses of fluconazole in the range of 1 to 12 mg/kg of body weight; a few received single doses. Administration was mainly by oral suspension or intravenous injection. Overall, 58 (10.3%) children reported 80 treatment-related side effects. The most common side effects were associated with the gastrointestinal tract (7.7%) or skin (1.2%). Self-limiting, treatment-related side effects affecting the liver and biliary system were reported in three patients (0.5%). Overall, 18 patients (3.2%) discontinued treatment due to side effects, mainly gastrointestinal symptoms. Dose and age did not appear to influence the incidence and pattern of side effects. Treatment-related laboratory abnormalities were uncommon, the most frequent being transient elevated alanine aminotransferase (4.9%), aspartate aminotransferase (2.7%), and alkaline phosphatase (2.3%) levels. Although 98.6% of patients were taking concomitant medications, no clinical or laboratory interactions were observed. The safety profile of fluconazole was compared with those of other antifungal agents, mostly oral polyenes, by using a subset of data from five controlled studies. Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%); vomiting and diarrhea were the most common events in both groups. The incidence and type of treatment-related laboratory abnormalities were similar for the two groups. In conclusion, fluconazole was well tolerated by the pediatric population, many of whom were suffering from severe underlying disease and were taking a variety of concurrent medications. The safety profile of fluconazole in children mirrors the excellent safety profile seen in adults.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89397

Safety profile of Nystatin
"WITH THERAPEUTIC USE 1. Toxicity from orally administered nystatin is extremely low. Dermal application or ingestion of even large quantities should produce only minor GI symptoms. Treatment is usually unnecessary.".........."Laboratory: Nystatin is not well absorbed orally. Unless GI inflammation is present, blood levels should not be detectable. Therapeutic or toxic blood levels have not been established."........"Toxicity due to nystatin is negligible. Even when large amounts have been ingested, ensuing symptoms have been minor. Charcoal, emesis and cathartic should not be necessary."......."ABSORPTION...FROM GI TRACT IS NEGLIGIBLE, & DRUG APPEARS IN FECES. WHEN DOSES OF 8 MILLION UNITS OR MORE ARE GIVEN, INDIVIDUALS WITH NORMAL RENAL FUNCTION MAY HAVE PLASMA CONCN OF ONLY 1-2.5 UG/ML. ... NYSTATIN IS NOT ABSORBED FROM SKIN OR MUCOUS MEMBRANES. [Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975. 1236]**QC REVIEWED**" http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~AAAnTaaFg:1.

Oral amphotericin B (Fungilin)
Oral amphotericin B (Fungilin) has been approved in most European countries for decades. It's used as a treatment and prophylaxis for a variety of oral and GI fungal infections, including oral thrush. In the United States, only an intravenous (IV) form of amphotericin B is available. how to obtain Amph B and Pure Nystatin .. http://www.drcranton.com/yeast/amphotericin.htm

Toxicities
Although the IV form of ampho B has long been dubbed ampho-terrible by PWAs due to its extreme side effects, the oral form is not toxic. No side effects have been noted at dosages under 3000 mg/day. Taking over 3000 mg/day can cause occasional stomach or intestinal discomfort, including diarrhea.
Dosage
The standard dose to treat symptoms is 400 mg/day, which may be raised if necessary. If you're taking oral ampho B for oral thrush, continue taking it for 2-3 days after your symptoms disappear. If you're taking it for GI infection, keep taking it for 2-3 weeks after your symptoms disappear.
http://www.thebody.com/content/art4743.html